Markets

DENTSPLY's (XRAY) Preliminary Q4 Results Cheer Investors

An image of a pen on an open laptop
Credit: Shutterstock photo

DENTSPLY SIRONA Inc.XRAY recently announced preliminary results for fourth-quarter 2018 wherein the top line surpassed the Zacks Consensus Estimate of $1.02 billion.

Revenues totaled at $1.06 billion, showing a fall of 2.9% year over year.

Adjusted earnings per share came in at 58 cents, beating the Zacks Consensus Estimate of 54 cents. Earnings declined 29.3% year over year.

Investors Cheerful

DENTSPLY's preliminary fourth-quarter 2018 results seem to impress investors. Share price of this Zacks Rank #3 (Hold) stock rose 4.6% to close at $49.13 since the release.

In the past year, shares of DENTSPLY have declined 12.1%, comparing favorably with the industry 's 1.3% fall. The current level is also lower than the S&P 500's rally of 3.3%.

DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise

DENTSPLY SIRONA Inc. Price, Consensus and EPS Surprise | DENTSPLY SIRONA Inc. Quote

2018 Results

Revenues in 2018 are expected at $4 billion, surpassing the Zacks Consensus Estimate of $3.94 billion. Revenues fell 0.2% from 2017.

Earnings per share for 2018 were $2.01, beating the Zacks Consensus Estimate of $1.97. The figure dropped 24.4% from 2017.

Quarter Highlights

Revenues in the fourth quarter are expected to see solid year-over-year increase of 4.6% in Europe and 1.4% in rest of the world. However, U.S. revenues declined 14.7% on a year-over-year basis in the quarter.

Fourth-quarter Consumable revenues increased 3.4% year over year. Notably, the segment benefited from a recovery in shipment levels at the company's European distribution center in Venlo, the Netherlands.

Technology & Equipment revenues declined 7.4% year over year.

2019 View

For 2019, DENTSPLY expects adjusted earnings per share within the range of $2.25-$2.40. The mid-point of $2.32 of the guided range lies above the Zacks Consensus Estimate of $2.15.

However, portfolio initiatives are expected to negatively impact 2019 revenues.

Key Picks

Some better-ranked stocks in the broader medical space are Abbott Laboratories ABT , Merit Medical Systems, Inc. MMSI and Surmodics, Inc. SRDX .

Abbott's long-term earnings growth rate is projected at 11.7%. The stock has a Zacks Rank #2 (Buy).

Merit Medical's long-term earnings growth rate is projected at 13%. The stock has a Zacks Rank #2.

Surmodics' long-term earnings growth rate is expected at 10%. The stock flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here .

Zacks' Top 10 Stocks for 2019

In addition to the stocks discussed above, wouldn't you like to know about our 10 finest buy-and-holds for the year?

From more than 4,000 companies covered by the Zacks Rank, these 10 were picked by a process that consistently beats the market. Even during 2018 while the market dropped -5.2%, our Top 10s were up well into double-digits. And during bullish 2012 - 2017, they soared far above the market's +126.3%, reaching +181.9%.

This year, the portfolio features a player that thrives on volatility, an AI comer, and a dynamic tech company that helps doctors deliver better patient outcomes at lower costs.

See Stocks Today >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Abbott Laboratories (ABT): Free Stock Analysis Report

Surmodics, Inc. (SRDX): Free Stock Analysis Report

DENTSPLY SIRONA Inc. (XRAY): Free Stock Analysis Report

Merit Medical Systems, Inc. (MMSI): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

XRAY SRDX MMSI ABT

Other Topics

Stocks

Latest Markets Videos